aap gains approval of bone replacement ceramic Cerabone

aap subsidiary and biomaterials specialist Coripharm has gained CE approval of its new bone substitute material Cerabone. Cerabone amounts to a new dimension in bone ceramics. It features an internally linked, highly stable system of pores identical in composition and structure to that of human bone. Cerabone's outstanding properties facilitate optimal bone integration in the organism, with a highly positive effect on the healing process. Cerabone is used to bridge bone defects in the entire skeleton.

With bone defects use is mainly made at present of the patient's own bone material or of bone material taken from other people. The benefits of using unorganic bone replacement materials such as Cerabone are ease of use and storage, avoiding further surgery and ruling out the risk of infection.

CE approval for Cerabone marks aap's take-off into orthobiology, a market with a future that with annual growth rates in excess of 50% is an extremely high-growth orthopedics sector. Market potential for orthobiologicals in the entire orthopedics market totals roughly $6.5 billion worldwide, the management says, while the market volume for bone replacement materials, amounting to $300 million, is expected to increase to up to $700 million by 2003.

By a combination of three core competences osteosynthesis (healing of bone fractures), endoprosthetics (replacement joints) and orthobiology (biological implants) aap as an orthopedics corporation enjoys a decisive competitive edge in developing and marketing biological implants for the muscular-skeletal organ system. And its sales structure enables aap to market Cerabone internationally right away.